Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
Authors:
- Federica GalotaFGFederica Galota
- Simone MarcheselliSMSimone Marcheselli
- Sara De BiasiSBSara De Biasi
- Lara GibelliniLGLara Gibellini
- Francesca VitettaFVFrancesca Vitetta
- Alessia FioreAFAlessia Fiore
- Krzysztof SmolikKSKrzysztof Smolik
- Giulia De NapoliGNGiulia De Napoli
- Martina CardiMCMartina Cardi
- Andrea CossarizzaACAndrea Cossarizza
- Diana FerraroDFDiana Ferraro
Open Access
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative autoimmune disorder of the central nervous system characterized by demyelination and neurodegeneration. Traditionally considered a T-cell-mediated disease, the crucial role of B lymphocytes in its pathogenesis, through different mechanisms contributing to inflammation and autoreactivity, is increasingly recognized. The risk of long-term disability in MS patients can be reduced by an early treatment initiation, in particular with high-efficacy therapies. The aim of this review is to provide an overview of the mechanisms of action of high-efficacy therapies for MS, with a focus on their impact on B cells and how this contributes to the drugs’ efficacy and safety profiles. Anti-CD20 monoclonal antibodies, Alemtuzumab, Cladribine and sequestering therapies encompassing Natalizumab and S1P receptors modulators will be discussed and emerging therapies, including Bruton’s Tyrosine Kinase inhibitors, will be presented.Keywords
This publication has 343 references indexed in Scilit:
- Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple SclerosisJAMA Neurology, 2021
- Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MSAnnals of Clinical and Translational Neurology, 2020
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsJAMA Neurology, 2020
- Serious safety events in rituximab‐treated multiple sclerosis and related disordersAnnals of Clinical and Translational Neurology, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of AlemtuzumabJAMA Neurology, 2017
- Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple SclerosisJAMA Neurology, 2016
- Fingolimod treatment promotes regulatory phenotype and function of B cellsAnnals of Clinical and Translational Neurology, 2015
- JC Virus in CD34+and CD19+Cells in Patients With Multiple Sclerosis Treated With NatalizumabJAMA Neurology, 2014
- Immunological Markers of Optimal Response to Natalizumab in Multiple SclerosisArchives of Neurology, 2012